Camila Gurgel dos Santos da Silva
Camila Gurgel dos Santos da Silva has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- André Luiz Leturiondo
Programa de Pós‐Graduação em Ciências Aplicadas à Dermatologia Universidade do Estado do Amazonas Manaus Amazonas Brazil
2 shared publications - Cynthia de Oliveira Ferreira
Laboratório de Biologia Molecular, Fundação Hospitalar Alfredo da Matta, Manaus, Amazonas, Brazil
2 shared publications - Felipe Jules de Araújo Santos
Programa de Pós‐Graduação em Ciências Aplicadas à Dermatologia Universidade do Estado do Amazonas Manaus Amazonas Brazil
2 shared publications - Silmara Navarro Pennini
Universidade do Estado do Amazonas, Brasil; Universidade do Estado do Amazonas, Brasil
2 shared publications - Sinésio Talhari
Programa de Pós‐Graduação em Ciências Aplicadas à Dermatologia Universidade do Estado do Amazonas Manaus AM Brazil
2 shared publications Anette Chrusciak‐Talhari
Programa de Pós‐Graduação em Medicina Tropical Universidade do Estado do Amazonas / Fundação de Medicina Topical Dr. Heitor Vieira Dourado Manaus Brazil
1 shared publication
Latest Publications
- 3 December 2024
- Published by Wiley in Tropical Medicine & International Health
- Vol. 30 (1) , 65-69
Sporothrix brasiliensis as the major causative species of the zoonotic outbreak of human sporotrichosis in the Brazilian Amazon
Background: Sporotrichosis is a neglected tropical disease and the most common subcutaneous mycosis, mainly caused by Sporothrix species, particularly S. brasiliensis, S. schenckii and S. globosa, which exhibit varying biological behaviours and virulence. The epidemic of sporotrichosis in Brazil, initiated in Rio de Janeiro in the late 1990s, rapidly spread to other states, including Amazonas in 2021. This study aimed to identify the specific Sporothrix species responsible for the human sporotrichosis outbreak in the Brazilian Amazon.Methods: A cross‐sectional study was conducted by enrolling clinically suspected cases of sporotrichosis attended at a reference dermatologic centre, in Manaus (Brazil). Biological material was collected from their skin lesions for culture (Mycosel) and for species identification (qPCR).Results: Sporothrix cultures were obtained from 150 cases. Sporotrichosis predominantly affected females (67.3%), aged 44.5 years on average, with lymphocutaneous lesions (72.7%). Sporothrix brasiliensis was identified in 89.3% of patients. Up to 83.3% of these patients reported contact with cats previously to the skin lesion, and the time‐spatial progression of the human cases followed the notification of cases in cats, in the metropolitan region of Manaus.Conclusion: Sporothrix brasiliensis is the dominant species in the zoonotic outbreak of human sporotrichosis in the Brazilian Amazon, with cats identified as the primary vectors. Effective sanitary control measures, education and responsible pet ownership are crucial to mitigating zoonotic sporotrichosis' impact in Brazil and preventing its spread to neighbouring Latin American cities.
- 3 December 2024
- Published by Wiley in Tropical Medicine & International Health
- Vol. 30 (1) , 65-69
Sporothrix brasiliensis as the major causative species of the zoonotic outbreak of human sporotrichosis in the Brazilian Amazon
Background: Sporotrichosis is a neglected tropical disease and the most common subcutaneous mycosis, mainly caused by Sporothrix species, particularly S. brasiliensis, S. schenckii and S. globosa, which exhibit varying biological behaviours and virulence. The epidemic of sporotrichosis in Brazil, initiated in Rio de Janeiro in the late 1990s, rapidly spread to other states, including Amazonas in 2021. This study aimed to identify the specific Sporothrix species responsible for the human sporotrichosis outbreak in the Brazilian Amazon.Methods: A cross‐sectional study was conducted by enrolling clinically suspected cases of sporotrichosis attended at a reference dermatologic centre, in Manaus (Brazil). Biological material was collected from their skin lesions for culture (Mycosel) and for species identification (qPCR).Results: Sporothrix cultures were obtained from 150 cases. Sporotrichosis predominantly affected females (67.3%), aged 44.5 years on average, with lymphocutaneous lesions (72.7%). Sporothrix brasiliensis was identified in 89.3% of patients. Up to 83.3% of these patients reported contact with cats previously to the skin lesion, and the time‐spatial progression of the human cases followed the notification of cases in cats, in the metropolitan region of Manaus.Conclusion: Sporothrix brasiliensis is the dominant species in the zoonotic outbreak of human sporotrichosis in the Brazilian Amazon, with cats identified as the primary vectors. Effective sanitary control measures, education and responsible pet ownership are crucial to mitigating zoonotic sporotrichosis' impact in Brazil and preventing its spread to neighbouring Latin American cities.
- 8 November 2023
- Published by Wiley in Tropical Medicine & International Health
- Vol. 28 (12) , 871-880
Treatment of cutaneous leishmaniasis with a sequential scheme of pentamidine and tamoxifen in an area with a predominance of Leishmania (Viannia) guyanensis: A randomised, non‐inferiority clinical trial
Objective: To determine whether a combination of a single intramuscular (IM) dose of pentamidine (7 mg/kg) followed by oral tamoxifen 40 mg/day for 20 days is non‐inferior to three IM doses of pentamidine 7 mg/kg in the treatment of cutaneous leishmaniasis with a margin of 15%.Methods: Phase II, randomised, controlled, open‐label, non‐inferiority clinical trial. Primary outcome was the complete healing of the lesions 6 months after starting treatment. Secondary outcomes were healing 3 months after starting treatment and determining the presence and severity of adverse effects (AE).Results: The research was concluded with 49 patients; Leishmania (Viannia) guyanensis was the most frequent species isolated. In the primary outcome, 18 (72%) (95% CI: 52.4%–85.7%) of the 25 patients allocated to the intervention group and 24 (100%) (95% CI: 86.2%–100%) of the control group (p = 0.015) met the established criteria of cure. There was no AE with tamoxifen.Conclusion: Although a 72% cure rate presented by the combination of tamoxifen and pentamidine was lower than in the control group that achieved a 100% cure, it is still a safe and is a clinically relevant result. It indicates that the therapeutic scheme evaluated may be a promising option for populations in remote areas, however it should be further studied, in order to include a larger number of patients.
- 8 November 2023
- Published by Wiley in Tropical Medicine & International Health
- Vol. 28 (12) , 871-880
Treatment of cutaneous leishmaniasis with a sequential scheme of pentamidine and tamoxifen in an area with a predominance of Leishmania (Viannia) guyanensis: A randomised, non‐inferiority clinical trial
Objective: To determine whether a combination of a single intramuscular (IM) dose of pentamidine (7 mg/kg) followed by oral tamoxifen 40 mg/day for 20 days is non‐inferior to three IM doses of pentamidine 7 mg/kg in the treatment of cutaneous leishmaniasis with a margin of 15%.Methods: Phase II, randomised, controlled, open‐label, non‐inferiority clinical trial. Primary outcome was the complete healing of the lesions 6 months after starting treatment. Secondary outcomes were healing 3 months after starting treatment and determining the presence and severity of adverse effects (AE).Results: The research was concluded with 49 patients; Leishmania (Viannia) guyanensis was the most frequent species isolated. In the primary outcome, 18 (72%) (95% CI: 52.4%–85.7%) of the 25 patients allocated to the intervention group and 24 (100%) (95% CI: 86.2%–100%) of the control group (p = 0.015) met the established criteria of cure. There was no AE with tamoxifen.Conclusion: Although a 72% cure rate presented by the combination of tamoxifen and pentamidine was lower than in the control group that achieved a 100% cure, it is still a safe and is a clinically relevant result. It indicates that the therapeutic scheme evaluated may be a promising option for populations in remote areas, however it should be further studied, in order to include a larger number of patients.